Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.2.0.727
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 30 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Dec. 31, 2014
Patent costs $ 84,745 $ 88,055 $ 212,226 $ 155,799    
Deferred setup and organization costs, amortization period     180 months      
Unrecognized tax benefits 0   $ 0   $ 0 $ 0
Theradex Systems, Inc [Member]            
Clinical costs charged to operations         $ 1,202,536  
Theradex Systems, Inc [Member]            
Clinical costs charged to operations $ 150,107 $ 93,581 $ 500,708 $ 173,233    
Percentage of clinical research and development costs 52.00% 28.00% 63.00% 35.00%    
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]            
Total estimated clinical costs to be charged to operations     $ 2,615,000      
Percentage of clinical trial service     60.00%      
Percentage of clinical center laboratory cost     40.00%